drugset / Trial / NCT00699608

An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

NCT00699608 ↗

Phase 3 Completed 91 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.

Timeline

Start
2008-07
Primary completion
2008-10
Completion
2008-10

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Eszopiclone vs Zopiclone; p = 0.267; Mean Difference (Final Values) -0.99 (95% CI -2.74 to 0.76); ANCOVA NCT00699608 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg —
Subject Zopiclone Small molecule 7.5 mg —